$MRSH

Doyle John Q sold $2.7M of MRSH

Doyle John Q (President and CEO) sold 16,656 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $161.71 ($2.69M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doyle John Q
Published Jun 3, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRSH
Neutral
medium confidence
Mentioned
$MRSH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The disclosure updates the record of management’s equity transactions; it does not by itself change company fundamentals.

02

Market read

Traders may monitor for sentiment/flow effects, but the 10b5-1 framing suggests limited directional conviction.

03

What to watch

Sale size is meaningful, but without context on total holdings, prior sales cadence, and whether the plan is regularly used, the signal may be overstated.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred on 2026-06-02

Background

The article is an SEC insider transaction disclosure (Form 4) for Marsh & McLennan Companies, Inc. (MRSH).

Company-level read

Ticker impact

$MRSHNeutralMedium confidence
Context

SEC Form 4 shows MRSH CEO sold 16,656 shares in an open-market transaction worth about $2.69M under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment/flow-driven rather than fundamental.

Evidence & confidence

The filing provides a concrete sale size and price, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

Minimal—single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated or large-value sales can still coincide with management’s private view of near-term risk or liquidity needs.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Doyle John Q

    President and CEO who sold shares.

  • Rule 10b5-1 plan

    Indicates the sale was pre-arranged, typically lowering interpretive weight.

Related articles

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%

$MRSHHighAI 9/10

Marsh & McLennan Companies (NYSE:MRSH) Stock Price Down 13.1% After Analyst Downgrade

Marsh & McLennan (NYSE:MRSH) fell 13.1% mid-day Wednesday after Piper Sandler cut its price target to $182 from $190 and kept a neutral rating. Shares traded as low as $180.97 and last at $160.70, after closing $185.00; volume rose to 3.04M. The article also cites recent analyst target changes and April 16 quarterly results: $3.29 EPS vs $3.21 consensus on $7.30B revenue.